Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target profile describes a specific cellular environment found in many malignancies, characterized by elevated ribonucleotide reductase (RR) activity and impaired Protein Kinase R (PKR) signaling (NIH, 2023). Ribonucleotide reductase is a rate-limiting enzyme responsible for converting ribonucleotides into deoxyribonucleotides, which are essential for DNA synthesis and repair; its upregulation in tumor cells supports rapid proliferation (PubMed: 10444016). The PKR pathway is a critical component of the innate immune system that detects double-stranded RNA and halts protein translation to prevent viral replication (UniProt: P19544). In many cancers, this pathway is suppressed—often through the activation of the Ras signaling pathway—to allow for uninterrupted growth (PubMed: 9843496). Therapeutic strategies, particularly oncolytic virotherapy, exploit these vulnerabilities for tumor-selective targeting. For instance, engineered Herpes Simplex Virus (HSV) mutants like G207 are designed with deletions in the viral RR gene (ICP6) and the PKR-evasion gene (gamma34.5) (PubMed: 10637341). These modifications restrict viral replication to cells that can compensate for the missing viral functions: those with high endogenous RR levels and defective PKR-mediated translation inhibition. This approach ensures that the virus selectively lyses tumor cells while sparing healthy tissue, simultaneously triggering a systemic anti-tumor immune response through the release of tumor-associated antigens and inflammatory cytokines (PubMed: 26515559).
Oncolytic viruses selectively replicate in cells with high ribonucleotide reductase activity and/or PKR pathway defects, leading to cell lysis and induction of anti-tumor immunity. Small molecule inhibitors of ribonucleotide reductase block DNA synthesis by depleting deoxyribonucleotide pools.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribonucleoside-diphosphate reductase (RR) and Eukaryotic translation initiation factor 2-alpha kinase 2 (PKR) (RR / PKR).